



**Innovative Sofra™ research presented
at prestigious European Molecular Biology Organization event**

- **Sofra™ research presented at European Molecular Biology Organization workshop**
- **Hudson Institute's A/Prof Gantier outlines inflammation blocking technology**
- **Robust intellectual property for commercial opportunities in growing markets**

Sydney, 18 May 2023: Innovative biotech company **Noxopharm Limited (ASX:NOX)** announces Associate Professor Michael Gantier from the Hudson Institute of Medical Research has presented research underlying the company's Sofra™ technology platform at the European Molecular Biology Organization (EMBO) Non-Coding RNA Medicine Workshop, held in Poznan, Poland.

The EMBO Workshop brings together leading professionals the academic and commercial worlds to discuss the latest progress in the field, with sessions covering everything from basic disease biology to therapeutic development.

A/Prof Gantier's presentation focused on ultra-short nucleic acid sequences known as oligonucleotides that have a broad range of potential therapeutic applications due to their ability to target specific inflammatory receptors (eg Toll-like receptors 7 and 8) to block inflammation at its source. This is the core foundation of the company's proprietary Sofra™ platform, and the technology can be readily adapted to treat a variety of conditions.

Noxopharm is working closely with the Hudson Institute, its strategic partner, to further progress this research and explore commercial opportunities in two main areas.

The first involves a new proprietary mRNA vaccine enhancer based on Sofra™ technology called SOF-VAC™, which aims to make a broad range of mRNA vaccines safer, like COVID vaccines, by reducing inflammation. The mRNA market has significant potential and growth prospects, with increasing interest worldwide in the ability of mRNA technology to target various diseases.

The second area relates to the development of novel drugs for autoimmune diseases such as psoriasis and lupus. Estimates of the number of individuals suffering from autoimmune diseases in the US alone range from 14 to 24 million cases¹, and the global immunology market is projected to grow from US\$92 billion in 2021 to US\$158 billion in 2028.²

Noxopharm CEO Dr Gisela Mautner said: "Associate Professor Gantier is a leader in the field, and this research represents a solid base of intellectual property on which to build several commercial opportunities. Unchecked inflammation from mRNA vaccines or disease affects a significant number of people worldwide, requiring new solutions and new technologies to be brought to market."



Hudson Institute A/Prof Michael Gantier said: “I was honoured to have been selected to go to Poland and present our research to an expert audience from around the world. This invitation shows the increasing interest in our work, and the potential it may offer for a novel approach to a variety of inflammation-related challenges.”

References

1. <https://www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm>
2. <https://www.globenewswire.com/en/news-release/2022/08/17/2499743/0/en/With-8-1-CAGR-Immunology-Market-Size-worth-USD-158-69-Billion-in-2028.html>

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US biotech company Nyrada Inc (ASX:NYR), which focuses on drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

About Hudson Institute of Medical Research

A global bioscience medical research leader, Hudson Institute’s sole focus is on powering breakthrough scientific discoveries into improved health care that will transform lives. We strive to improve human health through ground-breaking, collaborative, medical research discoveries and the translation of these to real world impact.

Hudson Institute scientists research five areas of medical need

- Inflammation
- Reproductive health and pregnancy
- Infant and child health
- Cancer
- Hormones and health

To learn more, please visit: www.hudson.org.au



Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Hudson Institute Media enquiries:

Rob Clancy

Communications & Media Manager

M: + 61 408 579 313

E: rob.clancy@hudson.org.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.